Compare SNBR & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SNBR | MOLN |
|---|---|---|
| Founded | 1987 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Home Furnishings | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 188.2M | 158.9M |
| IPO Year | 1998 | 2021 |
| Metric | SNBR | MOLN |
|---|---|---|
| Price | $4.59 | $4.86 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $10.00 | $8.38 |
| AVG Volume (30 Days) | ★ 683.0K | 1.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,682,296,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $285.71 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.49 | $3.36 |
| 52 Week High | $13.94 | $5.36 |
| Indicator | SNBR | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 24.51 | 54.87 |
| Support Level | $3.73 | $3.50 |
| Resistance Level | $8.94 | $5.36 |
| Average True Range (ATR) | 0.67 | 0.18 |
| MACD | -0.26 | -0.03 |
| Stochastic Oscillator | 0.31 | 38.04 |
Sleep Number Corp. is a wellness technology company engaged in the design, manufacturing, marketing and distribution of sleep solutions. The Company generates revenue by marketing and selling its smart beds directly to new and existing customers through its vertically integrated, exclusive, direct-to-consumer retail touch points including Stores, Online, Phone, and Chat (Total Retail). The products offered by the company are Mattresses, Bedding, Pillows and Furniture.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.